Arrow Generiques signs agreement to purchase selects assets in France from Teva


Arrow Generiques, the French unit of Aurobindo Pharma, has signed an agreement to purchase select commercial products in France from Teva.

Arrow Generiques will purchase the right, title and interest in products Calcium and Calcium Vitamin D3, including the  use of the OROCAL trademark.

The deal is subject to approval of the European Commission.  

After the receipt of approvals from European authorities, Arrow Generiques will merge these products with its existing commercial operations in France, and focus on maximising their potential.

Arrow Generiques and Teva plan to ensure continuity of the product supply to the market.

"This purchase will enable Arrow Generiques to continue to increase its branded products portfolio and leverage its position as a key player in the drug market."

This purchase will enable Arrow Generiques to continue to increase its branded products portfolio and leverage its position as a key player in the drug market.

Arrow Generiques focuses on selling generics for the retail and hospital markets in France since 2002.

Arrow Generiques entered a strategy of diversification with the purchase of the first branded products a few years ago to become a company balanced between generics / branded products / biosimilars within the retail and hospital markets.

A business unit with a sales and marketing team had been set up to particularly improve this business.

This deal will bolster its presence of Arrow Generiques and open new opportunities for the future.

Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.